Aytu Biopharma, Inc.
AYTU
$1.90
-$0.07-3.55%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 65.84M | 61.41M | 63.94M | 65.18M | 81.32M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 65.84M | 61.41M | 63.94M | 65.18M | 81.32M |
| Cost of Revenue | 19.21M | 17.23M | 15.94M | 16.13M | 24.76M |
| Gross Profit | 46.63M | 44.18M | 48.00M | 49.05M | 56.57M |
| SG&A Expenses | 39.26M | 40.14M | 40.44M | 42.04M | 46.68M |
| Depreciation & Amortization | 3.68M | 3.68M | 3.68M | 3.68M | 3.96M |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 64.30M | 63.65M | 62.65M | 64.62M | 77.59M |
| Operating Income | 1.54M | -2.24M | 1.29M | 565.00K | 3.74M |
| Income Before Tax | 3.16M | -2.42M | -1.41M | -10.38M | -10.30M |
| Income Tax Expenses | 841.00K | 1.48M | 2.55M | 2.14M | 1.30M |
| Earnings from Continuing Operations | 2.32 | -3.91 | -3.95 | -12.52 | -11.60 |
| Earnings from Discontinued Operations | -681.00K | -1.33M | -2.30M | -3.32M | -2.09M |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 1.64M | -5.24M | -6.25M | -15.84M | -13.68M |
| EBIT | 1.54M | -2.24M | 1.29M | 565.00K | 3.74M |
| EBITDA | 7.18M | 3.62M | 7.60M | 7.29M | 11.02M |
| EPS Basic | 0.20 | -0.97 | -1.14 | -2.86 | -2.64 |
| Normalized Basic EPS | 0.79 | 0.23 | 0.22 | -0.87 | -0.84 |
| EPS Diluted | -1.04 | -1.76 | -1.54 | -2.87 | -2.64 |
| Normalized Diluted EPS | 0.57 | 0.11 | 0.14 | -0.87 | -0.84 |
| Average Basic Shares Outstanding | 23.95M | 23.35M | 22.74M | 22.15M | 20.68M |
| Average Diluted Shares Outstanding | 31.41M | 28.74M | 25.77M | 22.15M | 20.68M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |